CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 15 No. 8
Pages: 1  2  
Next
 

Why Has Mortality Related to Pancreatectomy Declined?

August 1, 2006

SAN FRANCISCO—Nationally, the rate of in-hospital mortality associated with pancreatectomy for pancreatic cancer and other neoplasms has decreased in recent years, researchers reported at the 2006 Gastrointestinal Cancers Symposium (abstract 94). Although a greater proportion of these procedures are now being done in higher-volume hospitals, this shift only partly explains the drop in mortality. Investigators at the University of Massachusetts Medical Center led by James T. McPhee, MD, used a nationally representative sample—the National Inpatient Sample—to study trends in outcomes of pancreatectomy for neoplasms between 1998 and 2003.

The overall rate of in-hospital mortality for the entire 6-year period was 5.8%, Dr. McPhee said. When the data were stratified by year, the rate decreased significantly, from 7.7% in 1998 to 4.4% in 2003. A regression analysis further confirmed the drop in mortality, indicating that this outcome fell by 0.42% per year.

The investigators next stratified hospitals by volume, in a way that maintained equal numbers of patients in each group. By this process, low-volume hospitals were those performing fewer than four pancreatectomies for neoplasms each year; medium-volume ones, 4 to 13 per year; and high-volume ones, more than 13 per year. For the entire 6-year period, the in-hospital mortality rate was 9.6%, 5.5%, and 2.1% in low-, medium-, and high-volume hospitals, respectively. As found among hospitals overall, the rate fell within each group during the study period: from 14% to 8.3% in the low-volume facilities, from 4.3% to 3.5% in the medium-volume ones, and from 2.8% to 2.0% in the high-volume ones.

In a multivariate analysis including seven factors (age, sex, hospital surgical volume, hospital teaching status, year of resection, payer status, and comorbid conditions), compared with patients operated on in high-volume hospitals, those operated on in medium-volume ones had more than double the risk of death (odds ratio, 2.4) and those operated on in low-volume hospitals had more than quadruple the risk (odds ratio, 4.1).

"Interestingly, while in the univariate analysis, hospital teaching status was correlated with operative mortality, with urban teaching hospitals having superior outcomes, when adjusted for the other variables, specifically hospital surgical volume, hospital teaching status then became insignificant," Dr. McPhee noted.

Paradigm Shift?

The observed temporal pattern of in-hospital mortality could not be explained by disproportionate sampling of hospitals of various volumes over time or by differing patient case mixes at hospitals with differing volumes, according to Dr. McPhee. "This prompted us to ask this question: Could the decrease in mortality over time reflect a paradigm shift whereby a higher percentage of pancreatic resections are being performed at the higher-volume surgical centers?" he said.

Further analysis supported at least some role for this phenomenon: From 1998 to 2003, the proportion of all resections done annually in high-volume hospitals increased from 32% to 40%, and for medium- or high-volume hospitals, from 60% to 69%.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy